All Cornell University articles
-
NewsAMD3100 drug could boost immunotherapy in rare liver cancer
A rare liver cancer that primarily affects young people may soon have a new treatment option, after researchers found that an existing FDA-approved drug could enable immunotherapy to work effectively against tumours.
-
NewsBacterial ‘jumping genes’ found to control chromosome ends
Cornell researchers have discovered how transposons, or 'jumping genes,' insert themselves into bacterial chromosome ends, potentially transforming genetic engineering and advancing biotechnology. This breakthrough could reshape antibiotic research and unlock new drug discoveries.
-
NewsAI designs peptides for 'undruggable' diseases
A new AI-powered approach is tackling the challenge of 'undruggable' diseases by designing peptides that can bind to and destroy previously untreatable proteins.
-
NewsOff-switches developed for CRISPR-Cas3 technologies
AcrlC8 and AcrlC9 prevent the CRISPR-Cas3 machine from binding to its DNA target site, providing a safer way to engineer the genome.
-
ReportBeyond the lab: cell & gene therapy
The launch of our new series, "Beyond the Lab," promises to deliver high-level insights commissioned exclusively by Drug Target Review magazine. Our inaugural report is an exploration of the remarkable advancements in cell and gene therapy that are revolutionising the field of drug discovery.
-
NewsUS grant supports merging of maths and AI to push frontiers of science
Cornell University launches $11.3 Million Scientific Artificial Intelligence Centre to unlock the potential of human-AI collaboration in scientific discoveries.
-
NewsGround-breaking glycocalyx study could improve cancer immunotherapy
The researchers found that cancer cells with thicker glycocalyx barrier are better at evading immune cells.